Results 111 to 120 of about 22,112 (155)

B7 homolog 6 promotes the killing activity of natural killer cells against cervical cancer through the downstream ERK pathway of NKp30. [PDF]

Transl Cancer Res
Guo R, Chai O, Li C, Xu Y, Guo X.
europepmc   +1 more source

PD-1/PD-L1 blockade in HIV-associated advanced lung cancer: from mechanisms to clinical practice. [PDF]

Front Immunol
Chen R, Ren S, Tang H, Wu Q.
europepmc   +1 more source

A high density of T-cell lymphocytes and Tregs subset correlate to a worse survival in major salivary gland carcinomas. [PDF]

Sci Rep
Anconelli D, Vasuri F, Novelli L, Saragoni L, Messerini L, Saieva C, Cantone E, Muscatello L, Bartoletti G, Niccolai E, Amedei A, Franchi A, Ambrosio MR.   +12 more
europepmc   +1 more source

The Role of <i>Porphyromonas gingivalis</i> in Oral Carcinogenesis and Progression by Remodelling the Tumour Microenvironment: A Narrative Review. [PDF]

Cancers (Basel)
Starska-Kowarska K.
europepmc   +1 more source

TNFRSF17 as a complementary biomarker to PD-L1 for predicting the response to immunotherapy in urothelial bladder cancer. [PDF]

PLoS One
Chen J, Li B, Gan Y, Li P.
europepmc   +1 more source

Can the co-localization of CD8+, PD-1, PD-L1 AND PD-L2 patterns provide guidance in clinical outcomes of patients with head and neck cutaneous squamous cell carcinoma? [PDF]

Braz J Otorhinolaryngol
Bento GN, de Oliveira Santos AB, Matos LL, Faquin WC, Pai SI, Cernea CR.   +5 more
europepmc   +1 more source

Photochemical enhancement of PD-L1-SAP immunotoxin efficacy in non-small cell lung cancer cell lines. [PDF]

Front Immunol
Kozlíková M, Aukrust IKF, Rohlíčková M, Macháček M, Berg K, Weyergang A, Selbo PK.   +6 more
europepmc   +1 more source

Preclinical Evaluation of DB-1419, a Novel Bifunctional and Bispecific Anti-B7-H3 × PD-L1 Antibody-Drug Conjugate. [PDF]

Clin Cancer Res
Li C, Yao J, Yang J, Zhang Y, Qiu Y, Zhu Z, Hua H.   +6 more
europepmc   +1 more source

B7-H3 in Cancer Immunotherapy-Prospects and Challenges: A Review of the Literature. [PDF]

Cells
Mielcarska S, Kot A, Dawidowicz M, Kula A, Sobków P, Kłaczka D, Waniczek D, Świętochowska E.   +7 more
europepmc   +1 more source

Clinical value of tumor mutational burden for neoadjuvant and adjuvant immune checkpoint inhibitor in early-stage non-small cell lung cancer. [PDF]

J Immunother Cancer
C F Quintanilha J, Li G, Graf RP, Gasco A, Mitchell J, Huang RSP.   +5 more
europepmc   +1 more source